High-Tech Biotechnology fighting cancer

ScheBo®  Biotech AG is an innovative biotech company that is active in the fields of development, production and marketing of diagnostics.

Continuous innovation, strong customer focus and creative problem solving have made ScheBo® Biotech AG a worldwide leading manufacturer of unique products.

ScheBo® Biotech AG

  • independent
  • worldwide distribution network
  • exclusive and superior technologies and products
  • innovative and unique clinical diagnostic products
  • international research network

ScheBo media

 

The high sensitivity (c.80%) and high specificity (>90%) of the M2-PK stool test for colorectal cancer screening and detection, plus benefits for patients, laboratories and doctors, was presented at Focus 2010

  

Focusing on results with faecal pancreatic elastase and faecal lactoferrin from clinical studies conducted at the Royal Hallamshire Hospital in Sheffield, Dr David Sanders discusses the clinical value of faecal diagnostic assays

Korean Scientists have published the very newest data on the M2-PK test in the renowned specialist journal ‚Gut and Liver‘.

read more…

________________________________

ScheBo® Pancreas Elastase 1 Quick™ Canine test

ScheBo-Pancreas-Elastase-1-Quick-Canine

The stool test for the fast and reliable diagnosis/ exclusion of Exocrine Pancreatic Insufficiency in dogs is
… now also available as a rapid test

read more…

________________________________

New ScheBo® Pancreas Elastase 1 Quick™ test

Pankreas-ElastaseFaecal Pancreatic Elastase 1 – The Gold Standard for Non-Invasive Exocrine Pancreatic Function Testing … now also available as a rapid test

read more…

________________________________

2in1 Colorectal Cancer Screening Test

ScheBo-2-in-1New innovative combined rapid test to simultaneously detect the enzyme biomarker M2-PK and human haemoglobin for improved colorectal cancer screening.

read more…

________________________________

Meta-analysis published of faecal M2-PK in colorectal cancer screening

Authors conclude that „We recommend faecal M2-PK as a routine test for CRC screening“.

read more…

________________________________